Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Secret Squirrels hit! -- Ignore unavailable to you. Want to Upgrade?

To: musicguy who wrote (2761)	11/24/1998 6:32:00 PM
From: Wayne Rumball	Respond to of 12872

Wish I'd found it yesterday under a buck. nevertheless financial analysis to follow

To: musicguy who wrote (2761)	11/25/1998 7:24:00 AM
From: Wayne Rumball	Read Replies (1) \| Respond to of 12872

ACMI - forget it. Without further details I best guess calculate the possibility that the deal may only be adding 0.50/share to the book value of the company. It could be a lot more or it could also be reducing the book value, but since I don't know what they are giving up it is hard to say. Also the microbiology division is their main source of revenue, the cytopathology revenues are insignificant. Wasted enough time on this one, off to do some screening.